Agilent Technologies and Exact Sciences Corp, a leading provider of cancer screening and diagnostic tests, have announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences.
Resolution Bioscience’s blood-based diagnostic tests complements Exact Sciences’ precision oncology portfolio, with the new acquisition providing a more complete cancer treatment solution for patients, healthcare professionals, and biopharma partners. Financial terms of the agreement were not disclosed.
“We are pleased that Exact Sciences is acquiring Resolution Bioscience,” said Sam Raha, Senior Vice President, Agilent, and President, Diagnostics and Genomics Group. “Exact is a leading centralised laboratory for advanced cancer diagnostic testing with significant capabilities and resources in this area, which makes Resolution Bioscience a good strategic fit. This agreement will enable the talented Resolution Bioscience team to continue their work advancing diagnostic solutions for their customers and patients, a very positive outcome of this transaction.”
“We are excited to work with the Resolution Bioscience team to integrate their innovative diagnostics into our Precision Oncology portfolio,” said Brian Baranick, General Manager of Precision Oncology at Exact Sciences. “Resolution Bioscience’s high-quality liquid therapy selection platform perfectly complements our OncoExTra test, allowing Exact Sciences to help more cancer patients determine their best treatment options.”
Resolution Bioscience develops and commercialises next-generation sequencing-based precision oncology solutions. Agilent acquired the company in 2021.
